Ranolazine attenuates behavioral signs of neuropathic pain

Behav Pharmacol. 2009 Dec;20(8):755-8. doi: 10.1097/FBP.0b013e3283323c90.

Abstract

Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetanilides / administration & dosage*
  • Acetanilides / pharmacology
  • Acetanilides / therapeutic use
  • Animals
  • Ataxia / chemically induced
  • Behavior, Animal / drug effects*
  • Cold Temperature
  • Drug Evaluation, Preclinical
  • Injections, Intraperitoneal
  • Injections, Subcutaneous
  • Male
  • Nervous System Diseases / drug therapy
  • Nervous System Diseases / physiopathology
  • Neuralgia / drug therapy*
  • Pain Measurement
  • Pain Threshold / drug effects
  • Physical Stimulation
  • Piperazines / administration & dosage*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use
  • Random Allocation
  • Ranolazine
  • Rats
  • Rats, Sprague-Dawley
  • Reaction Time / drug effects
  • Sodium Channel Blockers / administration & dosage
  • Sodium Channel Blockers / pharmacology
  • Sodium Channel Blockers / therapeutic use

Substances

  • Acetanilides
  • Piperazines
  • Sodium Channel Blockers
  • Ranolazine